



(51) International Patent Classification:

C07D 277/68 (2006.01) **A61P 21/00** (2006.01)
A61K 31/428 (2006.01)

(21) International Application Number:

PCT/IB2012/054580

(22) International Filing Date:

5 September 2012 (05.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2011/079379

6 September 2011 (06.09.2011)

CN

(71) **Applicant** (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **CAO, Jun** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **ERB, Bernhard** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **FAIRHURST, Robin Alec** [GB/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **GRANDEURY, Arnaud** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HATAKEYAMA, Shinji** [JP/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **KOZICZAK-HOLBRO, Magdalena** [PL/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **LAI, Xinzong** [CN/CN]; Su-


zhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **LUSTENBERGER, Philipp** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **RIEBESEHL, Bernd** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **TUFILLI, Nicola** [IT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **ULLRICH, Thomas** [AT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **WU, Xiang** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **ZHOU, Janguang** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN).

(74) **Agent**: **CAMPBELL, Lachlan**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) **Title**: BENZOTHAZOLONE COMPOUND



(57) **Abstract**: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*